Ferrer acquires global rights to ASN90; an O-GlcNAcase inhibitor being developed by Asceneuron speciﬁcally for the treatment of progressive superior ophthalmoplegia (PSP) [Google translation]

ASN90 - Asceneuron

Feb 23, 2023